D

Dexcom

Markets real-time CGM devices and analytics

Engineering Supervisor - Packaging

Full-Time
€70.1k - €90.8k/yr
Senior
Athenry, Co. Galway, Ireland
In PersonFully onsite with 12-hour day shifts Friday through Sunday and alternate Thursdays; the schedule is expected to transition around Q1 2027.

About the job

Requirements
  • Formal or informal supervisory experience in a similar role, such as Technical Supervisor, Lead Technician, or Technical Team Lead, is essential.
  • Extensive experience in a technical role supporting manufacturing, such as Technician or Engineer.
  • An NFQ Level 7 or Level 8 qualification and 5–8 years of related experience are typically required.
  • Ability to read, analyze, and interpret scientific and technical documents related to equipment specifications.
  • Ability to write routine reports, shift reports, and correspondence.
  • Ability to present information effectively and respond to questions from supervisors, engineers, and managers.
  • Knowledge and experience with programmable logic controllers and automated production or process equipment, pneumatics, hydraulics, electromechanical systems, resistance welders, and packaging equipment.
  • Experience with process improvement projects, including improving yields and reducing downtime.
  • Ability to work hands-on in a fast-paced environment.
  • Knowledge of high-reliability, high-volume manufacturing equipment and processes.
  • Technical writing skills applied to manufacturing documentation and process development, including creating and revising technical documentation.
Responsibilities
  • Supervise and coordinate equipment technicians during the assigned shift, ensuring tasks are completed safely, efficiently, and to a high standard.
  • Review preventive and corrective maintenance activities in Maximo as part of maintenance oversight.
  • Delegate preventive maintenance tasks and oversee corrective maintenance activities.
  • Review and approve technician time and attendance records as required.
  • Supervise projects such as layout moves, equipment assembly, and validation report execution.
  • Deliver monthly performance updates through one-on-one meetings with each technician.
  • Coordinate or conduct technician training to maintain skill levels and support development.
  • Work alongside the Production Supervisor to ensure smooth and effective shift operations.
  • Provide hands-on support during escalation scenarios or when critical decisions are required.
  • Maintain and report department metrics such as Overall Equipment Effectiveness, yield, and other equipment-performance and maintenance key performance indicators.
  • Ensure compliance with safety procedures, including the Lockout/Tagout program.
  • Collaborate with cross-functional teams and external suppliers to sustain equipment and support equipment deployment and improvement initiatives.
  • Maintain accurate and current equipment documentation, including manuals, drawings, and specifications.

About the company

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 13% to $1.308 billion, with organic growth at 12%.
  • Gross margin hit 64.1%, and full-year 2026 revenue guidance rose to $5.25 billion.
  • Coverage now reaches over 7 million non-insulin patients across four major U.S. PBMs.

What critics are saying

  • Abbott’s FreeStyle Libre still pressures Dexcom pricing, reimbursement, and shelf space globally.
  • G7 15 Day is authorized in Canada but not yet sold, delaying revenue.
  • A major sensor accuracy recall would erase clinician trust and trigger payer restrictions.

What makes Dexcom unique

  • G7 15 Day gives Dexcom 15.5-day wear, beating shorter-cycle CGM rivals.
  • Dexcom combines sensors, apps, and Clarity analytics across type 1, type 2, gestational diabetes.
  • Health2Sync expands Dexcom’s connected-care moat in Australia, Singapore, and existing Japan workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
BioPharma Watch
Sep 14th, 2026
Dexcom promotes Jereme Sylvain to Chief Operating Officer.

Dexcom promotes Jereme Sylvain to Chief Operating Officer. Key Takeaway: Dexcom has announced the promotion of Jereme Sylvain to Chief Operating Officer. This strategic move is expected to bolster the company's operational capabilities and drive future growth. Sylvain's leadership is anticipated to play a crucial role in advancing Dexcom's objectives. Market sentiment analysis. Positive factors. * Jereme Sylvain's promotion reflects confidence in leadership. * The move may enhance operational efficiency at Dexcom. * This change could positively impact company direction. SAN DIEGO-(BUSINESS wire)-dexcom promotes Jereme Sylvain to Chief Operating Officer. Frequently asked questions. Who was promoted to Chief Operating Officer at Dexcom? Jereme Sylvain has been promoted to Chief Operating Officer at Dexcom. What is the significance of Jereme Sylvain's promotion? His promotion is expected to enhance operational efficiency and company growth.

Business Wire
Aug 31st, 2026
Quentin Blackford to join Align Technology Board of Directors.

Quentin Blackford to join Align Technology Board of Directors. Andrea L. Saia to Retire After 13 Years of Service Quentin Blackford TEMPE, Ariz. & SAN JOSE, Calif.-(BUSINESS WIRE)-Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign(R) System of clear aligners, iTero(TM) intraoral scanners, and exocad(TM) CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Quentin Blackford, President and Chief Executive Officer of iRhythm Technologies, as a director effective immediately and announced the retirement of Andrea Saia effective September 23, 2026. "We are pleased to welcome Quentin Blackford to our Board," said Kevin Conroy, Chairman of the Board of Align Technology. "Quentin is an exceptional leader whose accomplishments in global healthcare, medical technology, and digital innovation speak for themselves. His breadth of experience, strategic judgment, and commitment to advancing patient care will be tremendous assets to Align as we continue to shape the future of digital dentistry around the world." Mr. Blackford currently serves as President and Chief Executive Officer of iRhythm Technologies, a leading digital healthcare company focused on advancing cardiac care. He has served in this role since 2021. Before joining iRhythm, Mr. Blackford served as Chief Operating Officer of Dexcom, where he helped lead the company's global operations, corporate strategy, and international growth initiatives. Previously, he held senior finance and leadership positions at NuVasive and Zimmer Holdings. Mr. Blackford currently serves on the board of Alphatec Holdings and is a Certified Public Accountant (inactive). He earned dual Bachelor of Science degrees in Accounting and Business Administration from Grace College. Since joining the Board in 2013, Ms. Saia has played an important role in supporting Align's growth and transformation as a global medical device and digital dentistry leader. Her insights and counsel have contributed to the Board's oversight of the Company's strategic priorities, governance practices, and long-term growth initiatives. The Board and management team extend their sincere appreciation for her dedicated service and many contributions to Align. "Andrea has been an exceptional member of our Board and a trusted advisor to management," said Joe Hogan, president and CEO of Align Technology. "Her deep expertise, thoughtful counsel, and unwavering commitment to strong governance have helped guide Align through a period of significant growth and innovation. On behalf of the Board and the entire Align team, I want to thank Andrea for her many contributions and years of dedicated service." Mr. Blackford will be included in the company's slate of director nominees in the proxy statement for Align's 2027 Annual Meeting of Shareholders. In connection with Mr. Blackford's appointment, the Board increased its size to 11 directors. Effective upon Ms. Saia's resignation from the Board in September 2026, the size of the Board will decrease and again be comprised of ten directors. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign(R) System, the most advanced clear aligner system in the world, iTero(TM) intraoral scanners and services, and exocad(TM) CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 302.0 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 23.5 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align(TM) Digital Platform, its integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com. Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

TechDay
Aug 24th, 2026
Dexcom, Health2Sync partner on diabetes care in Asia.

Dexcom, Health2Sync partner on diabetes care in Asia. Mon, 24th Aug 2026 (Today) Dexcom and Health2Sync have formed a partnership focused on diabetes care in Australia and Singapore, linking glucose monitoring with digital chronic disease management. The partnership aims to support more connected care for people living with diabetes and their healthcare providers in both markets. It also reflects a broader push to expand digital health tools across Asia-Pacific. Health2Sync operates a digital chronic disease management platform that supports about 1.7 million users across the region. The company has built a presence in several Asian markets by offering tools that help people with diabetes and healthcare teams manage long-term care through digital services. Dexcom is known for its continuous glucose monitoring systems, which track glucose levels for people living with diabetes. The tie-up with Health2Sync reflects growing demand for connected healthcare technologies that support care coordination, simplify clinical workflows and enable more tailored approaches to chronic disease management. Regional push The deal gives Dexcom another partnership in Asia-Pacific as digital health companies seek to integrate monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both exploring greater use of remote monitoring and data-driven management for chronic conditions. Diabetes remains a major long-term health issue across the region, driving demand for systems that connect patient data with clinical decision-making. Companies in the sector have increasingly focused on linking devices, apps and care teams rather than offering standalone products. Health2Sync's scale in the region may give Dexcom access to a wider digital care network, while Dexcom's monitoring products add a stream of glucose data that can be incorporated into patient management. The companies have not disclosed commercial terms or product integration details. The announcement did not specify which Dexcom products or Health2Sync services would be included first in Australia and Singapore. It also did not say when any integrated offering would become available to users or healthcare providers. Company comments Both companies framed the partnership around a shared view that diabetes care can benefit from more connected management models. They said the arrangement is intended to help healthcare professionals and people living with diabetes access smarter, more connected ways to manage the condition. No financial details were released. The companies also did not outline any regulatory steps, local distribution arrangements or clinical partnerships tied to the agreement. More information is expected later. For now, the main disclosed fact is that Dexcom and Health2Sync are aligning their diabetes-related offerings across Australia and Singapore.

Ticker Report
Aug 21st, 2026
Silvant Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000. Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new […]

Yahoo Finance
Aug 12th, 2026
DexCom rallies 52.5% in three months as margins expand and earnings beat estimates

DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.